AstraZeneca and Oracle announce a partnership to use AI alongside real patient health data to improve and speed up clinical trial processes, including finding eligible patients and supporting trial monitoring. The companies describe the effort as an AI-driven approach to clinical research and recruitment.
Details vary by outlet. The Next Web reports that AstraZeneca and Oracle sign a non-binding term sheet, meaning the agreement’s terms are not final, and places the deal in the context of a broader wave of AI partnerships between pharmaceutical firms and technology providers. Business Line adds a specific implementation element, saying the initiative runs as AI-powered “real-world data trials” in Abu Dhabi, focused on accelerating recruitment and safety monitoring across multiple diseases. Wall Street Journal and CNA both frame the work as refining clinical research with AI, emphasizing the industry trend of tech–pharma collaborations.
